Wellington Management Group LLP Purchases 1,475,579 Shares of Cellebrite DI Ltd. $CLBT

Wellington Management Group LLP raised its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 93.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 3,049,904 shares of the company’s stock after purchasing an additional 1,475,579 shares during the quarter. Wellington Management Group LLP’s holdings in Cellebrite DI were worth $44,529,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. CWM LLC lifted its position in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the last quarter. SkyView Investment Advisors LLC boosted its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares during the period. Alamea Verwaltungs GmbH boosted its stake in shares of Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock valued at $444,000 after purchasing an additional 1,018 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in shares of Cellebrite DI by 45.1% in the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Insider Buying and Selling at Cellebrite DI

In related news, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CRO Marcus Jewell sold 12,562 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the transaction, the executive directly owned 427,128 shares of the company’s stock, valued at approximately $4,800,918.72. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 329,658 shares of company stock valued at $4,970,967 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $11.94 on Friday. Cellebrite DI Ltd. has a one year low of $9.58 and a one year high of $19.98. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of 54.28, a price-to-earnings-growth ratio of 1.78 and a beta of 1.15. The company’s 50-day simple moving average is $14.10 and its two-hundred day simple moving average is $13.70.

Wall Street Analyst Weigh In

CLBT has been the topic of several recent analyst reports. Lake Street Capital reduced their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday, August 14th. DA Davidson decreased their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings cut Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.70.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.